$MRNA $ABUS Today's MRNA press release is a legal flex masquerading as a scientific update. Well played, MRNA. Key takeaways: Primary purpose (announcing expansion of BARDA by $472M) could have been handled in 2-3 paragraphs. Secondary purpose is to forecast legal strategy. Note how MRNA surveys the totality of their scientific advances, covering not only mRNA-1273 but all other drugs and partnerships. It's a clear defense of turf, a corporate king of the mountain exercise. Post 1 of 2 investors.modernatx.com/new...
  • 4
4 Likes